302. Hepatocellular Carcinoma Occurs and Early After Treatment in HCV Genotype 3 Infected Persons Treated with DAA Regimens
Ghais Un Nabi Tayyab, MBBS1; Shafqat Rasool, MBBS1; Bilal Nasir, MBBS2 and Adee A. Butt, MD, MS3; 1Post Graduate Medical Institute/Ameer Ud Din Medical College/Lahore General Hospital, Lahore, Punjab, Pakistan; 2Well Cornell Medical College, Doha, Ad Dawhah, Qatar
Session: 41. Hepatitis
Thursday, October 3, 2019: 12:15 PM
Background. Treatment of HCV with directly acting antiviral agents (DAAs) is associated with a significant reduction in cardiovascular, metabolic and cancer risk. However, there are conflicting data regarding the risk of hepatocellular carcinoma (HCC) after DAA treatment. Risk of HCC in HCV genotype 3 infected persons after DAA therapy is not well known.
Methods. We prospectively studied HCV-infected persons initiated on treatment between October 2014 and March 2017 at two centers in Pakistan. All persons were free of HCC at study initiation. The occurrence of HCC was confirmed based on radiologic findings on a triphasic CT on 64 slice MDCT scanner. The treatment regimen was at the discretion of clinical care providers, taking into account the national guidelines and patient preferences. Patients were followed for 24 weeks after the completion of therapy. Informed consent was obtained from all participants.
Results. A total of 662 persons were initiated on treatment. Median age (IQR) was 59 (41, 57) years and 48.8% were male. At baseline, 49.4% were cirrhotic with 99% of cirrhotics having compensated cirrhosis. 91% were genotype 3 and SVR was attained in 91.9%. Treatment regimens used were: Sofosbuvir (SOF)/ribavirin (RBV)/pegylated interferon (PEG-IFN), 25.2%; SOF/RBV, 62.4%; SOF/RBV/dacavasvir (DCL), 10.6%; SOF/DCL, 2.0%. Incident HCC was detected in 42 patients (12.8%) in the six month period after treatment completion, and was exclusively observed in those with cirrhosis. In multivariable Cox regression analysis, SVR was associated with a reduction in HCC risk (HR, 95% CI: 0.95, 1.35; 0.60,0.85) while SOF/RBV/DCL regimens (compared with SOF/RBV/PEG-IFN) was associated with an increased risk of HCC (HR, 95% CI: 1.24, 1.40; 0.36). In K-M plots by treatment regimen, those treated with SOF/RBV, SOF/RBV/DCL, or SOF/DCL regimens had shorter HCC-free survival compared with those treated with a SOF/RBV/PEG-IFN regimen. (See figure)
Conclusion. In a predominantly genotype 3 cohort, incident HCC occurs commonly and early after treatment completion, and exclusively in those with pretreatment cirrhosis. SVR reduces but does not completely eliminate the risk of HCC. Treating HCV-infected persons before the development of cirrhosis may reduce future risk of HCC.
Disclosures. All authors: No reported disclosures.

304. A Surrogate Rodent Model for Studying Hepatitis C Virus-specific CD8 T-cell Impairment and Vaccine Prevention
Alex S. Hartlage, BSc1; and Amit Kapoor, PhD2; 1The Ohio State University College of Medicine, Dublin, Ohio; 2Nationwide Children’s Research Institute, Columbus, Ohio
Session: 41. Hepatitis
Thursday, October 3, 2019: 12:15 PM
Background. Virus-specific CD8 T cells are essential for control of acute hepatitis C virus (HCV) infections, yet spontaneously fail in most patients leading to lifelong chronicity and increased risk for severe liver diseases. Efforts to study HCV-specific CD8 T-cell impairment have been hampered by a lack of small animal models. Recently, we established a rat model of chronic HCV-like infection using a hepacivirus homolog identified in Rattus norvegicus. The nature of virus-specific CD8 T cell immunity in this model has yet to be determined.
Methods. We created a retrospective cohort of adults seen at 341 participating FQHCs in 19 US states. Inclusion criteria were: (1) clinical visit between January 01, 2012 and June 30, 2017; (2) ≥18 years of age. Outcomes included HCV testing proportion, stratified by diagnosis of opioid use disorder (OUD); treatment initiation rates; and sustained virologic response (SVR), defined as undetectable HCV RNA 3 months after treatment completion. We identified factors associated with testing, treatment initiation, and SVR using logistic regression.
Results. Of the 1,508,525 patients meeting inclusion criteria, 88,384 (5.9%) were tested for HCV, and 6,694 (9.8%) of individuals tested had reactive results. Of the 6,357 with HCV RNA testing (0.49%), 4,092 (64.4%) had detectable RNA. Twelve percent of individuals with chronic HCV and evaluable data initiated treatment. Of those, 86% reached SVR. Having commercial insurance (aOR, 2.16; 95% CI, 1.45–3.02), older age (aOR, 1.07; 95% CI, 1.06–1.10) and being Hispanic/Latino (aOR, 1.35; 95% CI, 1.01–1.83) or Asian/Pacific Islander (aOR, 1.84; 95% CI, 1.79–1.90) were independently associated with higher odds of treatment initiation after multivariable adjustment. Only 8% of individuals with chronic HCV were tested for HIV, and 15% of individuals with identified OUD were tested for HCV.
Conclusion. During the opioid epidemic, fewer than 20% of individuals with identified OUD were tested for HCV at evaluable FQHCs. In addition, approximately 10% of patients initiated treatment and SVR was lower than expected. Expansion of HCV management into community clinics must consider measures to monitor and evaluate treatment effectiveness, and to improve outcomes if care rates are low.
Disclosures. All authors: No reported disclosures.

303. Hepatitis C Virus Genotype 3B Infections Treated with Directly Acting Antiviral Agents
Jennifer H. Mayer, MD, MPH1; Jon Puro, MPH/HA2; Joshua A. Salomon, PhD3; and Benjamin P. Linas, MD, MPH4; 1Boston University School of Medicine/Boston Medical Center, Wayland, Massachusetts; 2Boston Medical Center, Boston, Massachusetts; 3Harvard Medical School/Fenway Research Institute, Boston, Massachusetts; 4OCHIN, Inc., Portland, Oregon; 5Stanford School of Medicine, Stanford, California
Session: 41. Hepatitis
Thursday, October 3, 2019: 12:15 PM
Background. Federally qualified health centers (FQHCs) serve diverse communities in the United States (US) and could function as important venues to manage hepatitis C virus (HCV) infections. Little is known on HCV outcomes in underserved communities as most of the current data are derived from clinical trials, commercially insured persons, or small health center samples. We aimed to determine the proportion of HCV testing, factors associated with treatment initiation, and real-world treatment outcomes in a large, national diverse sample of US FQHCs during the opioid epidemic.
Methods. We created a retrospective cohort of adults seen at 341 participating FQHCs in 19 US states. Inclusion criteria were: (1) clinical visit between January 01, 2012 and June 30, 2017; (2) ≥18 years of age. Outcomes included HCV testing proportion, stratified by diagnosis of opioid use disorder (OUD); treatment initiation rates; and sustained virologic response (SVR), defined as undetectable HCV RNA 3 months after treatment completion. We identified factors associated with testing, treatment initiation, and SVR using logistic regression.
Results. Of the 1,508,525 patients meeting inclusion criteria, 88,384 (5.9%) were tested for HCV, and 6,694 (9.8%) of individuals tested had reactive results. Of the 6,357 with HCV RNA testing (0.49%), 4,092 (64.4%) had detectable RNA. Twelve percent of individuals with chronic HCV and evaluable data initiated treatment. Of those, 86% reached SVR. Having commercial insurance (aOR, 2.16; 95% CI, 1.45–3.02), older age (aOR, 1.07; 95% CI, 1.06–1.10) and being Hispanic/Latino (aOR, 1.35; 95% CI, 1.01–1.83) or Asian/Pacific Islander (aOR, 1.84; 95% CI, 1.79–1.90) were independently associated with higher odds of treatment initiation after multivariable adjustment. Only 8% of individuals with chronic HCV were tested for HIV, and 15% of individuals with identified OUD were tested for HCV.
Conclusion. During the opioid epidemic, fewer than 20% of individuals with identified OUD were tested for HCV at evaluable FQHCs. In addition, approximately 10% of patients initiated treatment and SVR was lower than expected. Expansion of HCV management into community clinics must consider measures to monitor and evaluate treatment effectiveness, and to improve outcomes if care rates are low.
Disclosures. All authors: No reported disclosures.

305. Using Big Data to Re-Engage Hepatitis C-infected Persons: A UK Operational Delivery Network’s Experience
William Osborne, MBBS, MRCP, BSc, DTM&H1; Noorann Sheikh, MBBS2; Andrew Bosworth, PhD3; Sally Bukton, BSc4; David Mutimer, MBBS, MD5; Mamona Tahir, MBBS5 and Sowsan F. Abatani, MBBS6; 1Royal Stoke and University Hospital, Stoke-on-Trent, UK; 2University Hospitals Birmingham, Birmingham, UK; 3Public Health England Birmingham Laboratory, National Infection Service, Public Health England, Birmingham, UK; 4University Hospitals Birmingham, Birmingham, UK; 5University Hospitals Birmingham, Birmingham, UK; 6Public Health England, Birmingham, UK
Session: 41. Hepatitis
Thursday, October 3, 2019: 12:15 PM
Background. The prevalence of hepatitis C (HCV) varies across different risk groups in the UK. In England, responsibility for the co-ordination and administration of DAAs (direct-acting antivirals) to HCV PCR positive patients is with 22 regional
"Operational Delivery Networks" (ODNs). To attempt to eliminate Hepatitis C before 2030, Public Health England (PHE) and NHS England (NHSE) are attempting to re-engage previously diagnosed infected persons. To this end, ODNs have been supplied with historical antibody result data to target and reengage individuals for PCR testing and intervention if required. A study was designed to evaluate these data to help with informing ODN decisions. This study aimed to ensure that the data accurately identified patients that were PCR positive for HCV and thus fit the current criteria for receiving DAAs.

**Methods.** The regional ODN for the West Midlands was provided with 4540 patients with historical positive HCV antibody results, collected by a PHE surveillance system, to target for DAA intervention. DAA-treated patients had been excluded. Patient details were cross-referenced with all PCR results from January 1, 1996 up to January 1, 2019 at several regional laboratories (Public Health England Birmingham, the Queen Elizabeth Hospital, City and Sandwell Hospital) and national treatment data. Results. PCR data were found for 988, 276 (28%) of whom had received treatment. Of the 712 persons untreated, 347 (49%) were PCR negative and thus would not fit the criteria for receiving DAAs. 365 (51%) had a positive PCR result without a record of treatment would be eligible for DAAs (see Figure 1).

**Conclusion.** Our study suggests approximately one-third of patients identified by cross-referencing NHSE treatment and PHE epidemiological HCV antibody databases will be PCR-positive and suitable for re-engagement. Epidemiological data needed to be accurately curated when implementing public health control measures. Using "Big Data" to target interventions has several limitations but can be useful. DAAs for HCV are not without risk and administration should be clinically justified. Re-testing individuals prior to intervention is essential and other methods of elimination, for example "test and treat," may be more efficient and accurate.

**Disclosures.** All authors: No reported disclosures.

---

306. CD8+ T-Cell Responses to Chronic Hepatitis C in Pregnancy

**Stephanie Brooks, MD1, Samantha Cox, PhD2, Christopher Walker, PhD3 and Jonathan Honegger, MD2; Nationwide Children’s Hospital, Bexley, Ohio; 1The Ohio State University, Columbus, Ohio; 2Nationwide Children’s Hospital, The Ohio State University, Columbus, Ohio**

**Session:** 41. Hepatitis

**Background.** Chronic hepatitis C virus (HCV) infection is marked by stable, high-level viremia and a failed T-cell response. HCV-specific CD4+ helper T cells are rare, and CD8+ cytotoxic T cells are functionally exhausted or ineffective due to viral escape mutations. Postpartum, a subset of infected women experience a substantial drop in viremia. Preliminary data indicate that this unusual viral decline may be linked to a resurgence of HCV-specific CD4+ T cells producing Th1 cytokines. How improved CD4+ helper T-cell function might affect viral replication in this scenario is not established. Here we tested the hypothesis that improved CD4+ T-cell help mediates control of chronic HCV replication through enhanced CD8+ T-cell function.

**Methods.** We examined plasma HCV RNA viral load (VL) and HCV-specific T-cell responses in 33 women with chronic HCV during the third trimester (T3) and at 3 months postpartum (3P). HCV-specific CD4+ and CD8+ T-cell IL2 and IFNγ responses were measured by intracellular cytokine staining following stimulation of peripheral blood mononuclear cells with peptide pools corresponding to the HCV proteins NS3, NS4a, and NS4b.

**Results.** Median VL dropped from 5.87 log_{10} at T3 to 5.25 log_{10} at 3P (P < 0.001). Wilcoxon signed rank), with a wide range from +0.4 log_{10} to -4.2 log_{10}. The degree of decline correlated significantly with improved frequencies of HCV-specific CD4+ T cells producing IFNγ (P = 0.015 Spearman) but did not correlate with CD8+ T-cell changes. Nevertheless, improved T helper function correlated with increased HCV-specific CD8+ T-cell function (ΔCD4+IFNγ+ vs. ΔCD4+IL2+; Spearman p = 0.0148, r = 0.4271, graph 1; ΔCD4+IFNγ+ vs. CD8+IFNγ+ at 3P, P = 0.0039, Spearman, graph 2).

**Conclusion.** Despite no significant association between virus-specific CD8+ T-cell Th1 cytokine production and postpartum viral control, our data suggest that recovery of CD4+ T-cell help may augment CD8+ T-cell function. Further study incorporating viral genomic sequences to focus on intact class I epitopes is needed to clarify the relationship of improved CD8+ function and viral control in this unique model of immune restoration.

**Disclosures.** All authors: No reported disclosures.